Full Text
The Full Text of this article is available as a PDF (381.6 KB).
. 2006 May 1;6(3):240–244. doi: 10.7861/clinmedicine.6-3-240
18F-fluorodeoxyglucose PET/CT in cancer imaging
Peter J Ell
1, Irfan Kayani
2, Ashley M Groves
2
Peter J Ell, FMedSci
1Institute of Nuclear Medicine, UCL; Clinical Director, University College London Hospitals NHS Trust, London
University Chair and Director
Find articles by Peter J Ell
Irfan Kayani, MRCP FRCR
2Institute of Nuclear Medicine, University College London Hospitals NHS Trust, London
Specialist Registrar in Nuclear Medicine/Radiology
Find articles by Irfan Kayani
Ashley M Groves, MRCP FRC MD
2Institute of Nuclear Medicine, University College London Hospitals NHS Trust, London
Senior Lecturer in Multimodality Imaging
Find articles by Ashley M Groves
1Institute of Nuclear Medicine, UCL; Clinical Director, University College London Hospitals NHS Trust, London
2Institute of Nuclear Medicine, University College London Hospitals NHS Trust, London
Roles
Peter J Ell: FMedSci, University Chair and Director
Irfan Kayani: MRCP FRCR, Specialist Registrar in Nuclear Medicine/Radiology
Ashley M Groves: MRCP FRC MD, Senior Lecturer in Multimodality Imaging
Key Words: 18F-fluorodeoxyglucose, oncology imaging, positron emission tomography (PET)/computed tomography (CT)
© 2006 Royal College of Physicians
PMCID: PMC4953660 PMID: 16826854